Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Dentsply Acquisition Delivers Smiles

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The single worst word in the business lexicon? "Synergy." While it definitely has its uses, this term has also become empire-making CEOs' favorite justification for countless bad acquisitions. So when dental supply maker Dentsply (Nasdaq: XRAY  ) won the bidding for AstraZeneca's (NYSE: AZN  ) Astra Tech division and didn't include "synergy" anywhere in the deal's strategic rationale, investors must have flashed their pearly whites.

Much better phrases do show up in the $1.8 billion deal: "powerful cash flow generator" and "accretive to adjusted earnings." As in immediately accretive. Dentsply estimates the deal will add between $0.12 and $0.17 per share this year, and between $0.30 and $0.40 per share by year three of the combined company. Dentsply's top line should grow by 25%, to about $2.8 billion, as it becomes the third-largest player in the fast-growing dental implant segment.

Both companies' shareholders smiled upon the deal, even though the final price came in slightly lower than analysts estimated. AstraZeneca appears to be paring down its wide-ranging health care conglomerate, creating a more focused drug developer. For Big Pharma companies fearing the patent cliff -- and Astra has one of the steepest -- raising capital from asset sales and doubling down on a successful drug pipeline has become an increasingly legitimate strategy. The same logic fueled rumors of a potential Pfizer (NYSE: PFE  ) break-up.

While I understand that approach, drug companies' pipelines have looked more like black holes for the better part of a decade. Money goes in, but nothing ever seems to come out; for every Yervoy, which Bristol-Myers Squibb (NYSE: BMY  ) touts as proof that the process works, there have been countless flops. And whenever a drug company spins off a division, the value created for shareholders appears to walk out the door with it. For example, both of Bristol's spinoffs, Mead Johnson Nutrition (NYSE: MJN  ) and Zimmer (NYSE: ZMH  ) , have wildly outperformed their former parent company.

A laser-focused AstraZeneca may be able to find the next big drug blockbusters of the future. However, if it doesn't, things will get very, very ugly. If I had to choose between AstraZeneca and Dentsply, I'd definitely invest in the latter.

David Williamson owns shares of Pfizer. The Motley Fool owns shares of Zimmer Holdings. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1514578, ~/Articles/ArticleHandler.aspx, 10/24/2016 7:01:32 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:03 PM
AZN $30.72 Down -0.28 -0.90%
AstraZeneca CAPS Rating: ****
XRAY $58.30 Down -0.75 -1.27%
DENTSPLY Internati… CAPS Rating: *****
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
MJN $79.85 Up +0.45 +0.57%
Mead Johnson Nutri… CAPS Rating: ***
PFE $32.18 Down -0.36 -1.11%
Pfizer CAPS Rating: ****
ZMH.DL $0.00 Down +0.00 +0.00%
Zimmer Holdings CAPS Rating: ****